AbbVie, Neurocrine’s fibroid drug hits PhIII targets
A second late-stage study assessing AbbVie and Neurocrine’s experimental drug elagolix in women with uterine fibroids has met its primary endpoint.
Read More
Tag: ELARIS UF-II
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
